Search results
Zumutor is a leading Immuno-Oncology company in the space of targeted NK cell therapeutics. Our proprietary Human Antibody platform INABLR ™ is the genesis to our wholly owned, first-in-class therapeutic antibodies which target innate immunity and regulate the tumor micro environment.
Oct 16, 2018 · Building a world-class biologics company takes immense foresight, skill and dedication. It also takes a team of great people. At Zumutor, we focus on our people as much as we do on exploring the depths of science. We attract, retain and nurture scientific talent that shares our dream of pushing the boundaries of therapeutic research.
Zumutor Biologics Inc “Zumutor”, a Boston based biopharmaceutical company focused on developing unique novel therapeutics in immuno-oncology (I-O) today announces that the US Food and Drug Administration (FDA) has granted the company’s Investigational New Drug (IND) application for the novel drug ZM008 to initiate a Phase 1, first-in-human, clinical study for the
About Zumutor Biologics Zumutor is a novel immuno therapeutics company driving transformational change by harnessing the power of NK cells in modulating the Tumor Micro Environment (TME). HQ’d in oston, with labs in Bangalore, the company has developed a proprietary INABLR® platform consisting of multiple high diversity human antibody libraries which are mined through a combination of yeast and phage display
Jun 11, 2024 · Papers authored by Team Zumutor are listed here. Please contact us for further information. 2024; 2022; 2019; 2018; 2017; 2016; 2014; 2024; June 2024 An Explainable Machine Learning Data Analytics Method Using TIGIT-linked Genes for Identifying Biomarker Signatures to Clinical Outcomes. ... Author: Zumutor Biologics. J Clin Oncol 37, 2019 (suppl; abstr e14222) ASCOAbstract-May-16-2019.pdf. 2018;
Contact - Zumutor Biologics
Zumutor Biologics - Better health through better biologics
Zumutor Biologics Inc announces collaboration with Enzene Biosciences for it’s INABLR ... Zumutor’s lead product ZM008 received IND approval from USFDA recently and ready to enter Phase I clinical trial (FIH) in US. To learn more, visit us at : www.zumutor.com About Enzene: Enzene is an innova]on-driven biotech company a subsidiary of Alkem Laboratories Ltd. (one
Zumutor Biologics for Biotherapeutic Antibody Discovery Services 30th May, 2018, Bengaluru, India and Boston, USA Syngene International, a leading global Contract Research Services Company, has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immuno-oncology Company, to access Zumutor’s proprietary naïve human phage/yeast display library. This collaboration further enhances Syngene’s market-leading capabilities in Discovery ...
Bespoke Services - Zumutor Biologics
